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Amyotrophic lateral sclerosis (ALS) is a fatal, neurodegenerative disease that causes death of motor neurons.
ALSpatients andmousemodels of familial ALSdisplayorganismal levelmetabolic dysfunction,which includes
increased energy expenditure despite decreased lean mass. The pathophysiological relevance of abnormal
energyhomeostasis tomotorneurondisease remainsunclear. Leptin is anadipocyte-derivedhormone that reg-
ulates whole-animal energy expenditure. Here, we report that placing mutant superoxide dismutase 1 (SOD1)
mice in a leptin-deficient background improves energy homeostasis and slows disease progression. Leptin-
deficient mutant SOD1mice possess increased bodyweight and fat mass, aswell as decreased energy expend-
iture. These observations coincide with enhanced survival, improved strength and decreased motor neuron
loss. These results suggest that altering whole-body energy metabolism in mutant SOD1 mice can mitigate
disease progression. We propose that manipulations that increase fat mass and reduce energy expenditure
will be beneficial in the setting of motor neuron disease.
INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is an incurable neurodegen-
erative disease in which death of both upper and lower motor
neurons leads to progressive weakness and death. Disease patho-
genesis is linked to mitochondrial dysfunction, oxidative stress,
excitotoxicity, perturbation of RNA biology and impairment of
proteostasis (1–3).
A growing body of the literature highlights the presence of
metabolic perturbations in ALS (4–6). A subset of patients are
hypermetabolic, which is defined as ≥1.1 (≥10%) of the ratio
of measured resting energy expenditure (mREE) to calculated
resting energy expenditure (cREE) or mREE/cREE (7). ALS
patients show increased resting energy expenditure (+16–
18%) and decreased fat free mass (4,7–11). These abnormalities
are seen early in disease, are progressive and are present in both
sporadic ALS and familial ALS (fALS) patients (7). Similarly,
several mouse models of ALS, including transgenics, which
overexpress mutant forms of copper zinc superoxide dismutase1
(SOD1), show increased energy expenditure by indirect calorim-
etry, as well as decreased bodyweight (12,13). Mutant TAR
DNA-binding protein 43 (TDP-43) mice have also been reported
to exhibit altered organismal metabolism (14,15).
Previous studies have investigated the potential therapeutic
impact of dietary manipulations by administering a high-calorie
diet to mutant SOD1 mice (5,6,13). These studies report various
beneficial effects, including increased survival and improved
motor behavior in mutant mice. Because each study utilized dif-
ferent types of high-calorie diets, the extent to which the benefits
of these dietary manipulations can be ascribed to provision of a
specific nutrient(s) versus simply calories, per se, is unknown.
Furthermore, whether or not these dietary manipulations correct
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or improve the hypermetabolic phenotype of mutant SOD1 mice
have not been reported.
Leptin is an adipocyte-derived hormone that signals to periph-
eral tissues and the brain to induce satiety and increase energy
expenditure (16). Humans and mice that are null for the leptin
gene (ob) are hypometabolic, hyperphagic and morbidly
obese. Leptin-haploinsufficient (ob/+) mice possess 70% of
wild-type serum leptin levels and on average, 35% increased adi-
posity compared with wild-type controls (17,18).Ob/+mice are
neither obese nor hyperphagic, but are thought to have reduced
metabolic rates since they survive periods of fasting longer
than control counterparts (19). To test the notion that motor
neuron disease could be mitigated by changes in organismal me-
tabolism, we placed mutant SOD1 mice in the leptin-deficient
ob/+ or ob/ob backgrounds and investigated changes in body
composition, energy expenditure, motor function, and lifespan.
RESULTS
Leptin-deficient, mutant SOD1 animals demonstrate
blunted weight and fat loss
To investigate the effects of manipulating organismal metabol-
ism in a motor neuron disease model, we utilized hemizygous
mice harboring the G93A mutation, a well-characterized
model of ALS (20). G93A mice possess high copy numbers of
the human mutant SOD1 transgene, as well as display disease
symptoms, such as paralysis and muscle weakness similar to
ALS patients. Mutant SOD1 mice were placed in the background
of leptin-deficient ob animals in a two-step breeding strategy
(Fig. 1A). Genotypes were generated at expected frequencies
and litter sizes were normal (Supplementary Material,
Table S1). We refer to hemizygous G93A mutant SOD1
animals as SOD1;+/+, while G93A mutant SOD1 animals on
the mutant leptin heterozygote and homozygote backgrounds
are denoted as SOD1;ob/+ and SOD1;ob/ob, respectively. Non-
transgenic mice are denoted as +/+;+/+ (leptin wild type),
+/+;ob/+ (mutant leptin heterozygote) and +/+;ob/ob
(mutant leptin homozygote).
Previous literature has reported decreased adipose tissue and
circulating leptin levels in mutant SOD1 animals (13). To
assess the interaction between leptin-haploinsufficiency and
the SOD1 mutation, serum leptin levels were measured by
enzyme-linked immunosorbent assay (ELISA). Male and
female leptin-haploinsufficient (+/+;ob/+) mice possessed
50% of wild-type serum leptin levels at two time points, P90
and P120 (P , 0.05). There was no difference between
SOD1;ob/+ and +/+;ob/+ animals (Fig. 1B and C). In male,
but not female mice, there was a significant reduction in serum
leptin levels in SOD1;+/+ compared with +/+;+/+ at both
P90 and P120 (P, 0.05). These data show that the G93A muta-
tion does not affect circulating leptin levels in a leptin-
haploinsufficient background. We also observed sex-specific
effects in circulating leptin levels. SOD1;+/+ male, but not
female mice, showed decreased serum leptin levels compared
with +/+;+/+ controls.
To further investigate the effects of leptin deficiency on
whole-body metabolism in the mutant SOD1 mice, we recorded
bodyweight in both females and males, beginning at P40, an
early, asymptomaptic phase of disease until P120, a later,
symptomatic phase of disease (Fig. 2A and B). Although all
mice gained weight over time (F(12,372) ¼ 62.51, P , 0.0001),
there was a significant interaction effect between time and geno-
type (F(36,372) ¼ 3.63, P, 0.0001). At P60, an early time point
of disease, there were no significant differences in bodyweight
between mutant SOD1 animals and their control counterparts,
with the exception of SOD1;+/+ males (P ¼ 0.02 compared
with +/+;+/+ males) (Fig. 2A and B; Supplementary Mater-
ial, Table S2). Bodyweight differences between mutant SOD1
animals and non-Tg counterparts begin to largely diverge
around P90. At this time point, SOD1;+/+ mice weighed, on
average, 15% less than +/+;+/+ animals (P ¼ 0.02 and P,
0.001 in females and males, respectively), while SOD1;ob/+
mice weighed 5% less than +/+;ob/+ counterparts. By
P120, SOD1;+/+ mice weighed 18% less than +/+;+/+
animals (P , 0.01 and P, 0.0001 in females and males, re-
spectively), while SOD1;ob/+ mice weighed 15% less than
+/+;ob/+ animals (P , 0.001 and P, 0.02 and in females
and males, respectively).
However, the degree of weight loss was blunted in the ob hap-
loinsufficient background at several time points of disease (P60:
P, 0.02 for males, P90: P ≤ 0.02 for females and males). At
P120, female SOD1;ob/+ mice weighed 7% greater than
SOD1;+/+ counterparts (P ≤ 0.03). Similar to +/+;ob/ob
controls, SOD1;ob/ob female and male mice are also obese
and weighed more than twice the average bodyweight of
SOD1;+/+ and SOD1;ob/+ littermates at all-time points of
disease (P , 0.0001) (Fig. 2A and B; Supplementary Material,
Table S2).
Differences in bodyweight have been attributed to decreased
fat mass in mutant SOD1 mouse models (13). Consistent with
overall weight loss, both female and male SOD1;+/+ mice
showed a reduction in gonadal fat pads, the largest depot of
white adipose tissue (WAT), compared with +/+;+/+ litter-
mates. This observation was seen at both P90 and P120 (P ≤
0.05) (Fig. 2C). Compared with SOD1;+/+, SOD1;ob/+
mice possessed heavier gonadal fat pads (P , 0.04 and P,
0.008 at P90 and P120, respectively) (Fig. 2C). SOD1;ob/ob
mice possessed large gonadal fat pads, which weighed five
times more than both SOD1;+/+ and SOD1;ob/+ animals
(data not shown). Furthermore, at a later stage of disease
(P150), SOD1;+/+ mice are grossly cachexic, and this pheno-
type is attenuated in leptin-deficient SOD1;ob/+ mice
(Fig. 2D). Decreased adiposity in SOD1;+/+ mice and rescue
in SOD1;ob/+ mice were confirmed by dual-energy X-ray
absortiometry (DEXA) scanning. SOD1;+/+ mice demon-
strated a significant decrease in total body WAT content com-
pared with +/+;+/+ controls at P90 and P120 (P ¼ 0.047
and P , 0.001, respectively). This loss was attenuated in
SOD1;ob/+ mice (P , 0.02 at P90 and P120) (Fig. 2E).
Improved bodyweight in leptin-deficient mice was specific to
improvements in WAT. There were no differences among gen-
otypes in lean mass, an indicator of muscle mass, at P90. At
P120, SOD1;+/+ showed reduced lean mass compared with
+/+;+/+ mice (P ¼ 0.0006), although this loss was not
rescued inSOD1;ob/+mice (Fig. 2F). No significant weight dif-
ferences among genotypes were also observed in brown adipose
tissue (BAT) (Fig. 2G). There were also no significant differ-
ences in total bone mineral density (BMD) among genotypes, al-
though SOD1;+/+ animals had decreased abdominal BMD
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compared with +/+;+/+ mice. Decreased abdominal BMD
was not rescued in the SOD1;ob/+ mice (Fig. 2H).
Abnormal energy expenditure is attenuated
in leptin-deficient, mutant SOD1 animals
Are changes in bodyweight and fat mass associated with altera-
tions in overall energy expenditure? ALS patients and mutant
SOD1 animals have been reported to be hypermetabolic
(7,13). We therefore measured energy expenditure (VO2) by in-
direct calorimetry and found a significant effect of genotype on
average VO2 levels at P120 (F(3,32) ¼ 10.89, P, 0.001). Both
female and male SOD1;+/+ mice possessed significantly ele-
vated VO2 levels compared with +/+;+/+ mice (+16%,
P, 0.001) (Fig. 3A and B). Placing mutant SOD1 mice in a
leptin-deficient background blunted this hypermetabolic pheno-
type. Although SOD1;ob/+ mice still showed elevated VO2
levels compared with +/+;ob/+ controls (+10%, P ,
0.008), SOD1;ob/+ animals demonstrated a significant reduc-
tion in VO2 levels compared with SOD1;+/+ animals (P ¼
0.02). This effect was more pronounced in females compared
with males. Although there was a trend for male SOD1;ob/+
mice to possess lower VO2 levels compared with SOD1;+/+
animals, this did not attain statistical significance (Fig. 3B).
SOD1;ob/ob animals were significantly hypometabolic com-
pared with SOD1;+/+ and SOD1;ob/+ littermates (P ,
0.0001) (Fig. 3A and B). Reduced VO2 levels in leptin-deficient
mice was apparent during both the light (P, 0.0002) and dark
cycles (P ≤ 0.05) (Fig. 3C and D). Between +/+;+/+ and
+/+;ob/+ animals, no significant differences in average, light
and dark cycle VO2 levels were noted (Fig. 3A and B; Supple-
mentary Material, Fig. S1). Leptin null (+/+;ob/ob) mice
were also significantly hypometabolic compared with
+/+;+/+ and +/+;ob/+ littermates (P , 0.0001) (Supple-
mentary Material, Fig. S1).
The differences in bodyweight, body composition and energy
expenditure between SOD1;+/+ versus SOD1;ob/+ animals
could not be explained by differences in food consumption
(Fig. 3E), activity levels (Fig. 3F) or hyperthyroidism
(Fig. 3G). In contrast, obesity in leptin null +/+;ob/ob and
SOD1;ob/ob animals was associated with hyperphagia and
decreased activity levels (P, 0.0001 different from all geno-
types for both food intake and activity levels) (Fig. 3E and F).
Gene expression in skeletal muscle and BAT do not
correspond with the hypermetabolic phenotype of mutant
SOD1 mice
Previous studies have implicated skeletal muscle as a significant
contributor to the hypermetabolic phenotype of mutant SOD1
mice (21,22). To gain insight on the beneficial effects of our
genetic manipulation, we profiled genes involved in metabolism
in two kinds of skeletal muscle. In the soleus muscle, a two-way
ANOVA revealed significant main effects of genotype on gene
Figure1. (A) Two-step breeding strategy to generate leptin-deficient mutant SOD1 mice. In parenthesis are the expectedgenotype frequencies. (B) Serum leptin levels
from P90 and P120 mice. Leptin-haploinsufficient mice possess 50% of wild-type serum leptin levels (∗P , 0.05). Only SOD1;+/+ males possess significantly
decreased serum leptin levels at both P90 and P120 (aP , 0.05). n ≥ 7. Error bars+SEM.
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expression (F(3,101) ¼ 23.72, P , 0.0010) (Fig. 4A). Genes
involved in fatty acid oxidation (FAO), such as CPT1b,
MCAD and LCAD, as well as electron transport chain (ETC) ac-
tivity, such as ATP5g1, Cytc, Ndufa2 and COXIV, were signifi-
cantly decreased (or showed a trend towards reduced expression)
in SOD1;+/+ compared with +/+;+/+ animals. Partial
rescue of mRNA levels back to control levels was also observed
inSOD1;ob/+ animals for several of these genes, but this did not
reach significance. In the gastrocnemius (gastroc) muscle of
SOD1;+/+ mice, CPT1b and UCP3 levels were significantly
Figure 2. Leptin-deficient, mutant SOD1 mice display improved bodyweight and WAT mass. Female (A) and male (B) non-Tg mice gain weight between P40 and
P120. Although the bodyweight of mutant SOD1 animals start plateauing around P90, leptin-deficientSOD1;ob/+ andSOD1;ob/ob still weigh more compared with
SOD1;+/+ mice. n ≥ 7. (C) SOD1;+/+ animals have significantly less gonadal WAT (gWAT) than+/+;+/+ mice (aP ≤ 0.05), which is rescued in SOD1;ob/+
animals at P90 (#P, 0.04) and P120 (#P, 0.008). n ≥ 5. (D) P150 mice and respective gonadal WAT pads. Cachexia is attenuated in SOD1;ob/+ mice. (E) As
measured by DEXA scan, the total % of WAT is less in SOD1;+/+ compared with +/+;+/+ mice at P90 (aP ¼ 0.047) and P120 (aP, 0.001). This defect is
rescued in SOD1;ob/+ mice (#P , 0.02). n ≥ 3. (F) Total lean mass is decreased in P120 mutant SOD1 compared with non-Tg mice (a,bP ≤ 0.002). n ≥ 3. (G)
There are no differences in BAT weight among genotypes. n ≥ 5. (H) P120 mutant SOD1 animals possess significantly less abdominal BMD compared with
non-Tg controls (a,bP , 0.04). n ≥ 3. Error bars+SEM. aSignificantly different from +/+;/+/+, bsignificantly different from +/+;ob/+, #significantly different
from SOD1;/+/+.
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Figure 3.Leptin-deficient, mutant SOD1 females exhibit decreased energy expenditure. Average VO2 levels in female (A) and male (B) mice. In both sexes, average
VO2 levels are significantly elevated in SOD1;+/+ compared with +/+;+/+ mice (aP , 0.04). (A) Although SOD1;ob/+ females still show elevated energy ex-
penditure compared with +/+;ob/+ mice (bP , 0.008), they demonstrate reduced average VO2 levels compared with SOD1;+/+ mice (#P ¼ 0.02). SOD1;ob/ob
females also show decreased average VO2 levels compared with SOD1;+/+ mice (#P, 0.0001), with no difference compared with +/+;ob/ob mice. (B) Among
males, only SOD1;ob/ob mice show reduced VO2 levels compared with SOD1;+/+ and SOD1;ob/+ mice (#P, 0.0001). For both males and females, control
+/+;ob/ob mice show decreased VO2 levels compared with all other genotypes (∗P , 0.0001). For (A) and (B), n ≥ 8 except for ob/ob mice, n ≥ 3. (C) Energy
expenditure in P120 mutant SOD1 females across a 24-h time period. Gray shading indicates duration of dark cycle. (D) Quantification of data in (C), divided
into average VO2 levels during the light and dark cycles. Reduced VO2 levels in leptin-deficient mice are found during both cycles (
#P ≤ 0.05). (E) With exemption
of leptin null mice (∗P , 0.0001), all genotypesconsumed the same amountof foodduring a 24-h period.n ≥ 5 except forob/obmice,n ≥ 3. (F) With the exemptionof
leptin null mice (∗P , 0.0001), there were no significant differences in average activity levels (X-axis beam breaks) among genotypes, whether it was during the light
or dark cycles. All mice were more active during the dark phase (^P ≤ 0.0001). n ≥ 10 except for ob/obmice, n ≥ 3. (G) There are no differences in serum T4 levels
among genotypes. n ≥ 7. Error bars+SEM. aSignificantly different from +/+;/+/+, bsignificantly different from +/+;ob/+, #significantly different from
SOD1;/+/+ and/or SOD1;ob/+, ∗significantly different from +/+;+/+ and +/+;ob/+ or SOD;+/+ and SOD1;ob/+, ^ significantly different from light cycle.
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decreased compared with +/+;+/+ mice (P , 0.01, and
P, 0.001, respectively) (Fig. 4B). In neither case did leptin-
deficiency modulate these effects. No other changes were
detected in the genes surveyed. However, of note, UCP3 levels
were also significantly decreased in +/+;ob/+ compared
with +/+;+/+ mice (P , 0.001).
We also profiled gene expression in BAT tissue, since BAT
physiology can influence bodyweight and energy expenditure
(23,24). In all the metabolic genes surveyed, there were no sig-
nificant changes among genotypes (Fig. 4C). In sum, these
results suggest that gene expression changes in skeletal muscle
or BAT do not correspond to the hypermetabolic phenotype of
mutant SOD1 mice.
Leptin-deficient, mutant SOD1 animals live longer
We next wondered whether the improved organismal metabol-
ism observed in leptin-deficient mice are pathophysiologically
relevant to motor neuron disease progression. Does leptin defi-
ciency enhance survival in mutant SOD1 mice? We measured
lifespan in mutant mice of both sexes and found that
SOD1;ob/+ female mice live longer than SOD1;+/+ counter-
parts (Fig. 5A; Supplementary Material, Table S3). Compared
with SOD1;+/+, SOD1;ob/+ showed increased median (153
versus 170 days in SOD1;+/+ and SOD1;ob/+ mice, respect-
ively, P , 0.0030 by Wilcoxon test). Maximum lifespan was
also increased (176 versus 193 days in SOD1;+/+ and SOD1;
ob/+ mice, respectively). We also monitored disease onset
and progression in the mice. Disease onset is defined as the last
day of individual peak bodyweight. Early phase of disease is
defined as the duration of time between attainment of peak body-
weight and 10% loss of peak bodyweight, while the late phase of
disease is defined as the duration of time between loss of 10% of
bodyweight until the end stage (25). Disease onset was similar
between SOD1;+/+ and SOD1;ob/+ female mice (Fig. 5B;
Supplementary Material, Table S3). However, SOD1;ob/+
mice demonstrated increased duration of both the early (P ¼
0.049), as well as the late phases of disease (P ¼ 0.0356)
(Fig. 5C). An increase in both the duration of the early and late
phases of disease contributed to an overall increase in disease
duration of 17 days (P ¼ 0.0226). Although there was a
trend, male SOD1;ob,+ mice did not live significantly longer
compared with SOD1;+/+ counterparts (Fig. 5D; Supplemen-
tary Material, Table S3). Disease onset was also similar
between SOD1;+/+ and SOD1;ob/+ mice (Fig. 5E).
However, male SOD1;ob/+ mice demonstrated increased dur-
ation of the early, but not late, phase of disease (P ¼ 0.0136),
which contributed towards a modest increase in total disease dur-
ation of9 days (P ¼ 0.0367) (Fig. 5F). These data suggest that
placing mutant SOD1 animals in a leptin-haploinsufficient back-
ground slowed the rate of disease progression, and this effect was
stronger in females compared with males.
Due to the combination of obesity and hind limb weakness,
SOD1;ob/ob animals unfortunately developed pressure sores,
which necessitated euthanasia prior to limb paralysis (146
days). Thus, we were unable to determine whether a complete
loss of leptin activity had greater beneficial effects on survival
and disease duration than leptin haploinsufficiency.
Leptin-deficient, mutant SOD1 animals demonstrate
improved muscle function
We next examined motor function of bigenic (SOD1;ob/+ and
SOD1;ob/ob) mice to determine whether leptin deficiency
improves the motor phenotype of mutant SOD1 animals. In a
test of hind limb grip strength, by ANOVA, there were signifi-
cant effects of genotype on behavior among female mice
across multiple time points: P60 (F(5,55) ¼ 7.72, P, 0.0001),
P90 (F(5,45) ¼ 12.06, P , 0.0001) and P120 (F(5,33) ¼ 54.52,
P, 0.0001). Female SOD1;+/+ mice showed progressive
worsening of hind limb grip strength, and this was less severe
in SOD1;ob/+ mice (Fig. 6A). SOD;ob/+ animals showed a
20% improvement at P90 (P ¼ 0.03), which increased to
.40% at P120 (P , 0.0001). SOD1;ob/ob mice demonstrated
Figure 4. Expression of metabolic genes in skeletal muscle and BAT of mutant
SOD1 mice. (A) Isolated soleus muscle from P120 mice show significant reduc-
tions in transcript expression of genes involved in FAO, such as MCAD and
LCAD (aP , 0.05), as well as ETC activity, such as Ndufa2, COXIV and
ATP5g1 (aP , 0.05). Partial rescue was obtained in SOD1;ob/+ mice for
MCAD, Ndufa2, COXIV and ATP5g1, although this did not attain significance.
(B) Isolated gastrocnemius (gastroc) muscle from P120 mice do not show coor-
dinated changes in the transcript expression profiles of key metabolic genes,
except significant reductions between+/+;+/+ andSOD1;+/+mice in the ex-
pression of CPT1B (aP, 0.05) and UCP3 (aP , 0.001). No rescue was obtained
in SOD1;ob/+ for both genes. (C) Isolated BAT do not show changes in gene ex-
pression. n ≥ 3. Error bars+SEM.
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an even larger improvement in grip strength compared with
SOD1;+/+, as early as P60 (P, 0.01), which continued to
P120 (P, 0.0001). Similar results were observed for males
(Fig. 6C). The +/+;+/+ and +/+;ob/+ mice had equivalent
grip strength at all-time points for either sex (Fig. 6A and C).
Mice were also subjected to a treadmill test to assess muscle
endurance. There were significant effects of genotype on behav-
ior among female mice at P60 (F(3,39) ¼ 3.91, P, 0.02), P90
(F(3,32) ¼ 7.92, P, 0.0004) and P120 (F(3,19) ¼ 11.78, P,
0.0001). SOD1;+/+ mice performed worse than +/+;+/+
mice at P90 and P120 (P, 0.005 andP , 0.0001, respectively)
(Fig. 6B). However, SOD1;ob/+ ran significantly longer than
SOD1;+/+ mice (65.3+ 25.6 min versus 9.8+ 3.06 min, re-
spectively, P, 0.02) at P120, but not at P60 and P90. Similar
impairments were observed in mutant SOD1 males, although
no significant improvements were found in SOD1;ob/+ males
(Fig. 6D). The +/+;ob/ob and SOD1;ob/ob animals were too
obese to perform this assay and were therefore excluded. In
non-Tg mice, no significant differences in treadmill perform-
ance were noted. At a later time point of disease (P150), we
also observed home cage and tail suspension behaviors in
mutant mice and found that SOD1;ob/+ mice were more
Figure5.Leptin-deficient, mutantSOD1 mice demonstrate increasedsurvival. (A). Kaplan–Meir survival plots for female mice.SOD1;ob/+ females live longer than
SOD1,+/+mice (P ¼ 0.0030 by Wilcoxon test). n ≥ 13. (B) Kaplan–Meir survival plots for disease onset in female mice. Between genotypes, there is no significant
difference in disease onset, as measured by the day that peak bodyweight was attained (P ¼ 0.7035 by Wilcoxon test). (C) Compared with SOD1;+/+, SOD1;ob/+
females show increased duration of the early (#P ¼ 0.0409) and late phases of disease (#P ¼ 0.0356), as well as total disease duration (#P ¼ 0.0226). n ≥ 8.
(D) Kaplan–Meir survival plots for male mice. SOD1;ob/+ males do not live significantly longer than SOD1;+/+ mice (P ¼ 0.4202 by Wilcoxon test). n ≥ 26.
(E) Kaplan–Meir survival plots for disease onset in male mice. There is no significant difference in disease onset between male genotypes (P ¼ 0.1622 by Wilcoxon
test). (F) Compared with SOD1;+/+, SOD1;ob/+males show increased duration of the early (#P ¼ 0.0136) but not late phase of disease (P ¼ 0.4868), as well as an
overall increase in disease duration (#P ¼ 0.0367). n ≥ 15. Error bars+SEM.
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ambulatory and active compared with SOD1;+/+ mice (Sup-
plementary Material, Movies S1 and S2). These data indicate
that leptin-deficient, mutant SOD1 mice possess improved
motor strength and endurance, and these improvements occur
both at early and later stages of disease.
Motor neuron loss is blunted in leptin-deficient, mutant
SOD1 animals
Next, we investigated whether the beneficial effects of placing
mutant SOD1 animals in a leptin-deficient background is also
neuroprotective. To address this question, we counted motor
neurons in the lumbar spinal cord, the spinal cord segment
which shows the earliest signs of motor neuron degeneration.
At P90, there were no significant differences among genotypes;
however, at P120, there was a significant effect of genotype on
motor neuron number (F(3,11) ¼ 6.16, P ¼ 0.01) (Fig. 7A).
SOD1;+/+ displayed a 10% loss of lumbar spinal cord motor
neurons compared with +/+;+/+ controls (258+ 3.0 versus
278+ 6.8 motor neurons, respectively, P , 0.007), and this
was completely rescued in SOD1;ob/+ mice (P ¼ 0.003).
These data indicate that placing mutant SOD1 mice in a leptin-
deficient background protects against motor neuron death.
Localization of the leptin receptor in the ventral horn of the
spinal cord
Since reduction in circulating leptin levels showed benefits in the
mutant SOD1 model and leptin has central nervous system
actions (26,27), we wondered about the distribution of leptin
receptors in the spinal cord. Using an antibody against the best
characterized signal transducing leptin receptor (Ob-Rb), we
immunostained spinal cord sections from wild-type, non-Tg
mice. Ob-Rb immunoreactivity was seen in a minority of cells
in the ventral horn that were clearly not alpha motor neurons
(Fig. 7B). The immunopositive cells had small cell bodies with
processes extending into the neuropil near motor neurons.
Based on their morphology, Ob-Rb immunoreactive cells
appear to be glial, either a subpopulation of oligodendrocytes
or microglia. These observations suggest that any change in
leptin signaling in the spinal cord in the mice we have studied
is unlikely to be due to a direct effect on alpha motor neurons.
Figure 6. Leptin-deficient, mutant SOD1 mice display improved motor function. (A) Mutant SOD1 females show progressive hind limb weakening compared with
non-Tg controls (aP , 0.0001, bP , 0.002 and cP , 0.0003). Compared with SOD1;+/+ mice, SOD1;ob/+ and SOD1;ob/ob females possess improved hind limb
grip strength at several disease time points (#P , 0.01). Except for a modest decrease in hind limb grip strength of +/+;ob/ob compared with +/+;ob/+ animals at
P90 (∗P ¼ 0.02), there are no other differences among non-Tg controls. (B) Compared with non-Tg mice, both female SOD1;+/+ and SOD1;ob/+ mice show
decreased time on the treadmill (aP , 0.005, bP , 0.03); however, P120 SOD1;ob/+ mice run significantly longer than SOD1;+/+ mice (#P , 0.02). n ≥ 10.
(C) Mutant SOD1 males show progressive hind limb weakening compared with non-Tg controls (aP , 0.0001, bP , 0.006). Compared with SOD1;+/+ mice,
SOD1;ob/+ and SOD1;ob/ob males possess improved hind limb grip strength at several disease time points (#P ≤ 0.05). P120 +/+;ob/ob males show decreased
hind limb strength compared with other non-Tg controls (∗P ≤ 0.003). For all hind limb tests, n ≥ 10, except in +/+;ob/ob and SOD1;ob/ob animals, n ¼ 4. (D)
SOD1;+/+ andSOD1;ob/+males show decreased time on the treadmill compared with non-Tg controls (aP ≤ 0.0005, bP ≤ 0.03).n ≥ 4. Error bars+SEM. aSigni-
ficantly different from +/+;/+/+, bsignificantly different from +/+;ob/+, csignificantly different from +/+;ob/ob, #significantly different from SOD1;ob/+
and/or SOD1;ob/ob, ∗ significantly different from +/+;+/+ and +/+;ob/+ or SOD;+/+ and SOD1;ob/+.
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DISCUSSION
Metabolic abnormalities have been reported in ALS patients and
mouse models (4,13). Here, we present evidence that motor
neuron disease can be mitigated by reducing circulating leptin
levels, which in turn, alter organismal metabolism. First, we
confirm the presence of whole-animal metabolic defects in
G93A mutant SOD1 mice, a well-characterized model of
fALS (20). Second, we demonstrate that a genetic manipulation,
which improves organismal energy homeostasis, is both func-
tionally beneficial and neuroprotective. Placing mutant SOD1
mice in a leptin-deficient (ob/ob and ob/+) background, a
mouse model of hypometabolism, decreased the rate of weight
loss, increased WAT stores, and reduced energy expenditure.
Moreover, these beneficial effects coincided with enhanced sur-
vival, improved motor behavior, and decreased motor neuron de-
generation. Third, changes in organismal metabolism were not
associated with alterations in food intake, activity levels, BAT
weight and serum thyroid hormone levels. Fourth, we report
sex differences, especially in energy expenditure and survivor-
ship, which have not been considered in previous metabolic
studies (6,13). Whether the observed beneficial effects are
mediated by leptin-deficiency per se or a combination of altera-
tions in organismal metabolism and leptin deficiency is not im-
mediately evident. Further studies are needed in order to
clearly dissect these two possible mechanisms. Since SOD1-
causing mutations represent only a minor subset of ALS patients,
future experiments in SOD1-independent mouse models will
also be important.
This study provides the first genetic evidence that manipulat-
ing organismal metabolism modifies motor neuron disease pro-
gression. Epidemiological studies have shown that increased fat
mass and dyslipidemia are associated with slower disease pro-
gression in ALS patients (9,28,29). Furthermore, a retrospective
study reported that the presence of premorbid diabetes mellitus
type 2 in ALS patients was associated with delayed disease
onset (30). It is interesting that this ‘beneficial’ metabolic profile
is reminiscent of the phenotypes of leptin-deficient ob/ob ani-
mals, and to a certain extent, ob/+ animals (16,19,31). It is
worth noting that leptin antagonists have been clinically used to
treat cachexia in a mouse model of chronic kidney disease (32).
Our results confirm and extend previous reports showing
mutant SOD1 mice benefit from a high-calorie diet (6,13). The
terminology ‘high-calorie diet’ is broadly used, and in fact, the
dietary content and beneficial effects seen in these studies
varied significantly. For example, compared with a standard
rodent diet (22% fat, 55% carbohydrates and 23% protein), a
high-calorie diet in one study that reported increased survival
in mutant SOD1 mice consisted of 20% butter fat and 0.15%
cholesterol (13). In another study that reported improved
muscle function, but no change in survival, a high-calorie diet
consisted of 60% fat, 20% carbohydrates and 20% protein (6).
These observations raise the possibility that the provision of spe-
cific nutrient(s) enriched in these diets, not increased caloriesper
se, contribute to the observed beneficial effects. Prior studies, in-
dependent of mutant SOD expression, have emphasized that dif-
ferent ‘high-calorie diets’ vary in their effects on organismal
metabolism, and this specifically depends on the composition
Figure 7. Leptin-deficient, mutant SOD1 mice display rescued motor neuron loss despite lacking expression of the leptin receptor Ob-Rb by motor neurons. (A) At
P120, but not P90, significant motor neuron loss occurs in the lumbar spinal cord of SOD1;+/+ compared with +/+;+/+ mice (aP , 0.007). Motor neuron loss is
rescued in SOD1;ob/+ mice (#P ¼ 0.003). n ≥ 3. Error bars+SEM. (B) Ob-Rb localization in spinal ventral horn. (B1) Immunohistological staining of the spinal
cord for the leptin receptor Ob-Rb. The ventral horn is shown and the gray–white junction is outlined with a dashed line. The orientation is shown in the lower left: ‘D’,
dorsal; ‘V’, ventral; ‘M’, medial and ‘L’, lateral. In this differential contrast image, motor neurons are highlighted by the ‘,’ symbol and at least 5 are visible in this
focal plane. Numerous small immunoreactive cells are seen but motor neurons are not immunostained. Calibration bar ¼ 45 mm. (B2) Higher power image of a single
motor neuron (identified by ‘,’ symbol) and many small immunoreactive cells (identified by ‘∗’ symbol). These small immunopositive cells bear processes and
several are juxtaposed to the motor neuron. Calibration bar ¼ 23 mm.
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of the diet rather than the total calorie intake (33–35). An advan-
tage of our experimental design is that all groups consumed the
same standard rodent diet. It is noteworthy that SOD1;+/+ and
SOD1;ob/+ mice consumed equal amounts of food (3.7 g/day).
Our study demonstrates that by reducing energy expenditure (by
reducing leptin levels), the distorted organismal level energy
economy in the mutant SOD1 mice is corrected, and this is bene-
ficial in this model of ALS.
In this report, we also observed sex differences of our genetic
manipulation. Leptin-deficient SOD1;ob/+ females show
increased survival, improved motor function and decreased
energy expenditure in comparison to SOD1;+/+ animals. In
contrast, leptin-deficient SOD1;ob/+ males display a more
modest increase in survival and reduction in energy expenditure.
Furthermore, only SOD1;+/+ males, not SOD1;+/+ females,
showed decreased serum leptin levels compared with non-Tg
counterparts. Typically, WAT depot size correlates with circu-
lating leptin levels (36). However, leptin levels are influenced
by a number of factors, including various hormones (i.e. gluco-
corticoids, sex and reproductive hormones) (37), several of
which are altered in mutant SOD1 mice (13). It is likely that
these hormonal changes may mask alterations in circulating
leptin levels as a function of decreased WAT mass. These afore-
mentioned results are intriguing for a number of reasons. First,
these results confirm previous observations of sex-dependent
differences in ALS disease progression, in which the underlying
mechanisms remain enigmatic (38–41). Second, these results
suggest an interaction between sex, metabolic dysfunction and
motor neuron disease progression. Sexual dimorphic responses
to various experimental manipulations have previously been
reported in ALS patients and mouse models (41–44). Ovariecto-
mized female G93A mutant SOD1 mice demonstrate worsened
disease progression; moreover, disease symptoms are attenuated
by estradiol treatment (45,46). Since estrogen plays an important
role in mitochondrial function and aging (47), these observations
may indicate that sex-dependent manipulations may be influ-
enced by the interaction between estrogen and mitochondrial
metabolism. Along the same lines, a recent report describes sex-
specific effects of the transcriptional co-activator and metabolic
regulator peroxisome proliferator-activated receptor gamma,
coactivator 1 alpha (PGC-1a) on mutant SOD1-induced
disease progression and links this observation to differential ex-
pression of the neurotrophic factor VEGF and estrogen receptor
ERRa in the nervous system (41). It will be interesting to further
investigate how leptin deficiency affects mitochondrial function
in both sexes as well as how PGC1a and its downstream targets
are affected in leptin-deficient mutant SOD1 animals.
One major question raised by this work is whether further
amelioration of mutant SOD1-induced motor neuron disease
could be achieved with a greater or lesser reduction in serum
leptin levels. One of the limitations of this genetic experiment
is the inability to precisely regulate leptin levels. In our
bigenic mice, leptin has been reduced from birth to either
50% or 0% of wild-type levels. We show that in the context
of motor neuron disease, even a 50% global decrease in serum
leptin levels is associated with improvements in both metabolic
and neuromuscular functions. Observations in the SOD1;ob/ob
mice hint at the possibility that further reductions in serum
leptin levels may have a more pronounced beneficial effect.
These observations are consistent with recent work showing
that blocking spinal cord leptin activity can reverse and
prevent pain behaviors induced by sciatic nerve injury (48).
The long form of the leptin receptor (Ob-Rb), which is thought
to mediate majority of leptin’s biological signals (37,49), has
been reported to be expressed in the spinal cord, although loca-
lized to either sensory neurons or astrocytes (48). Our immuno-
histological staining result does not suggest Ob-Rb expression
by motor neurons and instead suggests possible expression by
glial cells. Leptin signaling may indirectly affect motor neuron
survival by modulating signaling pathways in astrocytes, which
in turn has been shown to play a role in motor neuron disease pro-
gression (50). However, since leptin can be neurotrophic (at least
during development) (51), reducing leptin signaling may have un-
intended consequences. Manipulations that more tightly regulate
leptin levels should be considered for the future.
Our study begins to shed light on which tissues may be respon-
sible for improved energy homeostasis. Contrary to previous
reports (21,22), we do not find evidence that changes in gene ex-
pression in skeletal muscle correspond with the hypermetabolic
phenotype of mutant SOD1 mice. We found that FAO and ETC
gene expression were significantly reduced, particularly in
soleus muscle, of mutant SOD1 mice at a time point when hyper-
metabolism is present. This result is consistent with previous
observations of impaired muscle mitochondrial respiration
(22). We also found that UCP3 expression was reduced, suggest-
ing that uncoupled energy in the form of heat, may not be contrib-
uting to elevating energy expenditure. The disparity between our
results and previous reports may have several sources. Our mice
were congenic (C57BL/6), whereas previous reports utilized
mixed FVB/N or SJL-B6 strains (13,22,52). Background geno-
type is well known to influence metabolic parameters (53,54),
as well as disease progression in mutant SOD1 mice (55,56).
In addition, at the time point tested, muscle denervation has
already occurred, which may confound interpretation of the
observed metabolic gene profile (57). Given our observations
that mutant SOD1 mice are hypermetabolic at this time point,
it is possible that other tissue(s) may significantly contribute to
elevating energy expenditure. Further investigation is required
to see if tissues, including liver, brain and even bone, may influ-
ence whole-animal metabolism in this mutant SOD1 mouse
model of ALS.
Interesting recent work attempted to manipulate energetic
status of muscle in mutant SOD1 mice by transgenic overexpres-
sion of PGC1a, a master regulator of mitochondrial biogenesis
(58). This manipulation rescued some motor defects, but did
not increase survival. In another experiment, Eschbach and col-
leagues placed mutant SOD1 mice in the background of PGC1a-
deficient mice and found decreased survival in the bigenic mice
(41). The effects of these manipulations on organismal metabol-
ism remain to be explored. We favor the view that impairment in
muscle mitochondrial function may be a significant contributor
to motor weakness in the mutant SOD1 model of ALS, but its
concrete role in contributing to organismal dysfunction in this
model requires further query.
In sum, our results support the hypothesis that organism-level
metabolic dysfunction is pathophysiologically relevant to motor
neuron disease. Manipulating leptin activity and other metabolic
pathways that ultimately alter body composition and energy
expenditure may be intriguing therapeutic targets to treat ALS
patients.
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MATERIALS ANDMETHODS
Mouse care
Since female G93A mutant SOD1 mice are poor breeders, male
hemizygous G93A mutant SOD1 mice on the C57BL/6 back-
ground (Strain # 004435, Jackson Laboratory, Bar Harbor,
ME, USA) were crossed with female mice heterozygote for the
obese gene (ob/+) (Strain # 000632, Jackson Laboratory).
From the F1 generation, mutant SOD1;ob/+ males were
crossed with ob/+ females to generate the F2 generation. The
genotypes of mutant SOD1 mice were determined by PCR
using tail snip DNA, as described elsewhere (59), while the gen-
otypes of ob mice were determined by PCR using tail snip DNA
and a subsequent restriction enzyme digest as described on the
Jackson Laboratory website. Mice were fed a standard diet
(23% protein, 22% fat, 55% carbohydrates) and were housed
at 228C on a 12-h light–dark cycle. All animals were treated in
strict accordance with the National Institutes of Health Guide
for the Care and Use of Laboratory Animals. All experiments
were approved by the Children’s Hospital of Philadelphia Insti-
tutional Animal Care and Use Committee.
Analyses of disease onset and survival
The early and late stages of disease were determined as previously
described (25,60). Disease onset is defined as the last day of in-
dividual peak bodyweight before gradual loss occurs. The stages
of disease are defined as follows: the early stage of disease is
defined as the duration of time between peak bodyweight until
loss of 10% of peak bodyweight. The late stage of disease is
defined as the duration of time between 10% loss of peak body-
weight until the end stage of disease. The end stage of disease is
defined as the day when an animal could no longer right itself
within 30 s for three consecutive trials when placed on its side.
Animals were euthanized at the end stage of disease.
Motor behavior
All tests were performed at P60, P90 and P120. Mice were habi-
tuated to the procedure room before testing. Grip strength
assays were performed as previously described (60). Endurance
was tested using a mouse treadmill apparatus (Columbus Instru-
ments). Mice were tested on the following speed categories for
a total time of 140 min: 80 mm/s (20 min), 120 mm/s (60 min)
and 170 mm/s (60 min). The endpoint of testing was defined as
when an animal ceased to run, even when gently prodded with a
wooden tongue depressor. The total time duration on the treadmill
(sum of all three speed categories) was analyzed for each mouse.
Body composition measurements
Bodyweights were assessed weekly for at least 13 weeks. BAT
and gonadal WAT were dissected and weighed at the indicated
age. Total lean mass, % of WAT and BMD were determined
by DEXA (PIXImus DEXA; GE). DEXA imaging was per-
formed by the Mouse Phenotying, Physiology and Metabolism
Core at the University of Pennsylvania.
Indirect calorimetry, food intake and activity
Animals were initially weighed and acclimated to the test cage.
Volume oxygen (VO2) and volume carbon dioxide production
(VCO2) were measured every20 min using the Oxymax Com-
prehensive Laboratory Animal Monitoring System (CLAMS)
(Columbus Instruments) and are reported as average VO2 per
hour normalized to bodyweight (mL/h/kg). Using the CLAMS
machine, activity counts by infrared beam interruptions and
food intake were simultaneously measured. More specifically,
food intake was measured by deducting the weight of powder-
ized food pellets at the end of experimentation from the starting
weight at the beginning of experimentation. To complement this
experiment and to control for a novel environment that may
affect feeding behavior, we also performed a more ‘manual’ ex-
periment, wherein a set weight of food pellets was placed at the
same time each day into a clean home cage, which held a mouse.
The next day the weight of the remaining pellets was recorded
and deducted from the starting weight. This experiment was per-
formed for 14 days straight. The bodyweight of each mouse was
also recorded daily. Results for each genotype were similar to
that acquired from the CLAMS.
Leptin and thyroid hormone 4 serum measurements
Retro-orbital bleeds were performed fromad libitum fed P90 and
P120 mice using microhematocrit capillary tubes (Fisherbrand).
Blood was allowed to coagulate for 15 min at room temperature,
and spun at 7500×g for another 15 min. Serum was collected
and stored in 2808C until use. Leptin and thyroid hormone 4
(T4) assays were performed by the University of Pennsylvania
Radioimmunoassay/Biomarkers Core Facilities, as described
elsewhere using a coated tube assay for T4 measurements
(MPBiomedicals) and a sandwich ELISA for leptin measure-
ments (EMD Millipore).
Quantitative real-time PCR
Muscle was homogenized using the Qiagen Tissue Lyser II and
RNA was isolated using the TRIzol method (Invitrogen).
Adipose tissue was homogenized on ice using an electric hom-
ogenizer, and RNA was isolated using the TRIzol method com-
bined with Qiagen RNEasy mini columns. Total RNA was
reverse transcribed using the ABI high-capacity cDNA synthesis
kit (Applied Biosystems) or Qiagen Quantiscript Kit. Real-time
PCR analysis was performed as previously described for muscle
(61) and for adipose tissue (62). All primers are available upon
request.
Motor neuron counts
Mice were sacrificed at P90 and P120. After perfusion fixation
with freshly prepared 4% paraformaldehyde in 0.1 M phosphate
buffer (pH ¼ 7.4), the spinal cord from lumbar segment 1 to
sacral segment 1 (L1–S1) was dissected out of the vertebral
canal, post-fixed overnight at 48C, and then cryoprotected by
overnight immersion in 30% sucrose in 0.1 M phosphate buffer
(pH ¼ 7.4). Using the Jung-Frigocut 2800N cryostat (Leica),
consecutive 40 mm-thick sections were collected and Nissl
stained. Motor neurons were identified by their location in
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Rexed lamina IX and characteristic size and polygonal morph-
ology. We counted the number of motor neurons in every 6th
spinal cord section from an individual animal and these values
were summed. In previous work, we found that this estimate of
the number of motor neurons can be reliably used to make
group comparisons (63).
Immunohistology
P90 C57Bl/6 mice were perfused and fixed according to the
protocol described above. The following day post-fixation, the
tissue was blocked into 2–3 mm segments, frozen in dry ice
and cryostat sections (10 mm) were prepared with a Jung Frigo-
cut 2800N (Leica). Tissue sections were thaw mounted on
Superfrostw Plus slides (VWR), permeabilized in PBS + 1%
Triton X-100 (for 10 min), blocked in PBS + 5% fetal calf
serum, FBS (for 1 h) and extensively washed with PBS. Slides
were incubated with a rabbit antibody directed against mouse
leptin receptor Ob-Rb (Alpha Diagnostics, catalogue #
OBR12-A) at 1:1000 in PBS + 5% FBS overnight at room tem-
perature in a sealed humidified chamber. Control slides were
incubated with PBS + 5% FBS. The following day, the slides
were washed in PBS, incubated with biotinylated anti-rabbit
antibody (Amersham Pharmacia Biotech) diluted 1:250 in
PBS + 5% FBS for 3 h. This was followed by PBS washing, in-
cubation with ABC reagent (Vector), and visualized with 0.03%
3,3′-diaminobenzidine HCl and 0.003% H2O2. Slides were
dehydrated, defatted with xylene, coverslipped with Permount
and imaged on an Axio Imager.A2 (Zeiss).
Statistics
Statistics were analyzed using GraphPad Prism 5.0. Student’s
t-tests were used in comparisons between two-group data and
multivariate ANOVAs, including repeated measures ANOVAs,
were used in comparisons among three or more groups of data.
Post hoc tests were performed to confirm significance. Non-
parametric statistical analysis, including Kruskal–Wallis tests,
was used to analyze behavior from the treadmill tests. Kaplan–
Meier survival plots and Gehan–Breslow–Wilcoxon tests were
utilized to analyze lifespan. The threshold for significance was
set at P ≤ 0.05.
SUPPLEMENTARYMATERIAL
Supplementary Material is available at HMG online.
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